IEEE unveils eHealth standards projects

IEEE, an association for technical professionals, has launched several standards development projects designed to further innovation in eHealth.

The new IEEE Standards Association’s (IEEE-SA’s) projects are intended to produce standards to support plug-and-play and interoperable communications across personal health devices and three-dimensional (3D) medical systems.

The most recent standards under development include five that are designed to improve wellness monitoring and preventive healthcare and support independent living, wellness and fitness. These are:

  • IEEE P11073™-10404a “Health Informatics - Personal Health Device Communication - Device Specialization-Pulse Oximeter Amendment;”
  • IEEE P11073-10407a “Health Informatics - Personal Health Device Communication - Device Specialization-Blood Pressure Monitor Amendment;”
  • IEEE P11073-10408a “Health informatics--Personal health device communication Part 10408: Device specialization-Thermometer Amendment;”
  • IEEE P11073-10415a “Health Informatics - Personal Health Device Communication - Device Specialization-Weighing Scale Amendment,” and
  • IEEE P11073-10420a “Health informatics -- Personal health device communication Part 10420: Device specialization-Body composition analyzer Amendment.”

The IEEE-SA also launched projects designed to yield standards that would help advance 3D imaging and simulation in healthcare.

“The launch of these new standards-development projects for eHealth is another indication of the IEEE-SA’s commitment to improving quality of healthcare and wellbeing of people worldwide,” said Konstantinos Karachalios, managing director, IEEE-SA, in a statement.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.